NKGen Biotech

June is Alzheimer's & Brain Awareness Month.

According to the 2026 Alzheimer's Association Facts & Figures Report, more than 7 million Americans are living with Alzheimer's disease, highlighting the ongoing need for awareness, education, and scientific research.

This month, we recognize those affected by Alzheimer's disease and support efforts to advance understanding of brain health and neurodegenerative diseases.

NKGen Biotech (OTC:NKGN) announces the activation of three additional U.S. clinical sites for its ongoing Phase 2 study of troculeucel in moderate Alzheimer's disease, expanding patient access and supporting enrollment efforts across multiple regions.

Learn more: https://bit.ly/4dkqNmI

$NKGN

NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer’s disease. SANTA ANA, Calif., May 19, 2026 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical...

This May, we recognize ALS Awareness Month alongside the global community. ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative condition that affects nerve cells responsible for movement, gradually impacting the ability to move, speak, eat, and breathe.

We acknowledge patients, families, and caregivers affected by ALS and recognize the importance of continued scientific research to better understand neurological diseases. NKGen remains committed to advancing neurodegenerative disease research to help patients with limited treatment options.

NKGen Biotech, Inc. (OTC: NKGN) will present at the 8th Annual Neuroimmunology Drug Development Summit in Boston on Thursday, April 16, 2026, at 11:00 AM ET.

NKGen CEO, Dr. Paul Y. Song, M.D., will highlight the therapeutic rationale supporting troculeucel’s use in neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia (FTD). The presentation will include an overview of the Company's expanding mechanistic dataset, including evidence that troculeucel selectively targets autoreactive T cells and may modulate key neuroinflammatory pathways implicated in disease progression. Dr. Song will also review clinical observations from early-stage studies, including encouraging biomarker trends and reductions in neuroinflammatory signals measured in cerebrospinal fluid.

Read the full press release: https://nkgenbiotech.com/nkgen-biotech-to-present-troculeucel-mechanism-data-in-alzheimers-and-frontotemporal-dementia-at-the-neuroimmunology-drug-development-summit/

$NKGN

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit SANTA ANA, Calif., April 9, 2026 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that i...

April is Parkinson’s Disease Awareness Month, a time to recognize the individuals and families affected by this progressive neurodegenerative disease and to highlight the importance of continued research and innovation across the field.

At NKGen Biotech, we are dedicated to advancing science in neurodegenerative diseases and supporting efforts that deepen understanding and drive future therapeutic progress. While there is still much to learn, ongoing collaboration across the scientific and medical communities continues to move the field forward.

This month, we stand with patients, caregivers, clinicians, and advocates to raise awareness and reinforce the importance of sustained investment in Parkinson's disease research and education.

NKGen Biotech (OTC: NKGN) reported combined Phase 1 data for troculeucel at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2026), showing 100% of Moderate Alzheimer’s patients remained stable or improved, with 50% improving to milder cognitive function, alongside dose-related cognitive benefit and signs of early durability through 12 months. Biomarker analysis for plasma GFAP correlations aligned with clinical outcomes and, together with a favorable safety profile, support continued evaluation in the ongoing Phase 2 trial.

See press release for more information: https://bit.ly/4bIH6HK

$NKGN

NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function. Exploratory plasma GFAP correlations are consistent with observed clinical o...

During Brain Awareness Week, we join the global neuroscience community in celebrating the complexity of the brain and highlighting the critical importance of neuroscience research. With more than 55 million people worldwide living with dementia—a number expected to rise dramatically in the coming decades—the need for continued discovery, collaboration, and innovation, has never been greater.

At NKGen Biotech, we are dedicated to developing innovative therapies for neurodegenerative diseases and working to transform scientific discoveries into meaningful treatments that bring hope to patients and families affected by these conditions.

NKGen Biotech (OTC:NKGN) will present Phase 1 integrated clinical and biomarker analyses for troculeucel in Alzheimer’s disease at the upcoming AD/PD™ 2026 conference in Copenhagen.

The Company will deliver an oral presentation on dose-response assessments of cognitive measures and a poster on biomarker associations, including plasma Glial Fibrillary Acidic Protein (GFAP).

Read the full press release here: https://bit.ly/46OKoHX

$NKGN

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026 SANTA ANA, Calif., March 10, 2026 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced upcom...

Today on National Caregivers Day, we honor the strength and compassion of caregivers, especially those supporting loved ones living with Alzheimer's. Even in the face of emotional and physical challenges, your dedication inspires our commitment to advancing Alzheimer's clinical research with urgency and purpose.

Today, we see you. We thank you. We stand with you.

NKGen Biotech, Inc. (OTC: NKGN) announces the appointment of Bruce L. Miller, M.D., a globally recognized dementia expert, to its Scientific Advisory Board. Dr. Miller’s leadership in neurodegenerative disease research further strengthens the Company’s scientific foundation as it advances its clinical programs and explores potential applications in frontotemporal dementia (FTD).

Read the full press release: https://bit.ly/4pTjeWW

$NKGN

NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board Dr. Miller’s appointment further enhances NKGen’s scientific and clinical advisory capabilities as the Company advances its research in Alzheimer’s and other related neurodegenerative diseases. SANTA ANA, Calif., January 22, 2026 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Compa...